{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:14:20Z","timestamp":1791346460139,"version":"4.3.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s00213-013-3068-y","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T12:00:30Z","timestamp":1364990430000},"page":"1023-1036","source":"Crossref","is-referenced-by-count":79,"title":["Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders"],"prefix":"10.1007","volume":"231","author":[{"given":"Laura C.","family":"Politte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"3068_CR1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","volume":"15","author":"MG Aman","year":"2005","unstructured":"Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adoles Psychopharmacol 15:869\u2013884","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/CHI.0b013e3181bfd669","volume":"48","author":"MG Aman","year":"2009","unstructured":"Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48:1143\u20131154","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","volume":"20","author":"MG Aman","year":"2010","unstructured":"Aman MG, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R (2010) Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adoles Psychopharmacol 20:415\u2013422","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR4","series-title":"Text revision","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, Text revision. American Psychiatric Association, Washington","edition":"4"},{"key":"3068_CR5","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","volume":"141","author":"LT Anderson","year":"1984","unstructured":"Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195\u20131202","journal-title":"Am J Psychiatry"},{"key":"3068_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","volume":"19","author":"LT Anderson","year":"1989","unstructured":"Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J (1989) The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19:227\u2013239","journal-title":"J Autism Dev Disord"},{"key":"3068_CR7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B (2007) Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545\u2013550","journal-title":"Biol Psychiatry"},{"key":"3068_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2009.0022","volume":"20","author":"LE Arnold","year":"2010","unstructured":"Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S, DiSilvestro R, McDougle CJ, McCracken J, Vitiello B, Aman MG, Scahill L, Posey DJ, Swiezy NB (2010) Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adoles Psychopharmacol 20:83\u201393","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","volume":"44","author":"J Blair","year":"2005","unstructured":"Blair J, Scahill L, State M, Martin A (2005) Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 44:73\u201379","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","volume":"36","author":"M Campbell","year":"1997","unstructured":"Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36:835\u2013843","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR11","unstructured":"CenterWatch (2012) Drug Information: FDA-Approved Drugs. http:\/\/www.centerwatch.com\/drug-information\/fda-approvals\/ . Accessed 15 Nov 2012"},{"key":"3068_CR12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","volume":"62","author":"NC Chen","year":"2001","unstructured":"Chen NC, Bedair HS, McKay B, Bowers MB Jr, Mazure C (2001) Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 62:479\u2013480","journal-title":"J Clin Psychiatry"},{"key":"3068_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4088\/JCP.v65n0119","volume":"65","author":"SA Cohen","year":"2004","unstructured":"Cohen SA, Fitzgerald BJ, Khan SR, Khan A (2004) The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 65:110\u2013113","journal-title":"J Clin Psychiatry"},{"key":"3068_CR14","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","volume":"65","author":"AH Corson","year":"2004","unstructured":"Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ (2004) A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531\u20131536","journal-title":"J Clin Psychiatry"},{"key":"3068_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/cap.2006.00136","volume":"17","author":"HS Duggal","year":"2007","unstructured":"Duggal HS (2007) Ziprasidone for maladaptive behavior and attention-deficit\/hyperactivity disorder symptoms in autistic disorder. J Child Adoles Psychopharmacol 17:261\u2013263","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nurt.2010.04.001","volume":"7","author":"CA Erickson","year":"2010","unstructured":"Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurother J Am Soc Exp Neurother 7:258\u2013263","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"3068_CR17","first-page":"415","volume":"17","author":"A Fido","year":"2008","unstructured":"Fido A, Al-Saad S (2008) Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract Int Journal Kuwait Univ Heal Sci Cent 17:415\u2013418","journal-title":"Med Princ Pract Int Journal Kuwait Univ Heal Sci Cent"},{"key":"3068_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/1044546041649129","volume":"14","author":"RL Findling","year":"2004","unstructured":"Findling RL, McNamara NK, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL (2004) Quetiapine in nine youths with autistic disorder. J Child Adoles Psychopharmacol 14:287\u2013294","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1203\/PDR.0b013e31819e7203","volume":"65","author":"E Fombonne","year":"2009","unstructured":"Fombonne E (2009) Epidemiology of pervasive developmental disorders. Pediatr Res 65:591\u2013598","journal-title":"Pediatr Res"},{"key":"3068_CR20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00787-007-0656-6","volume":"17","author":"O Gencer","year":"2008","unstructured":"Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E (2008) Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry 17:217\u2013225","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"3068_CR21","first-page":"340","volume":"26","author":"G Gobbi","year":"2001","unstructured":"Gobbi G, Pulvirenti L (2001) Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci JPN 26:340\u2013341","journal-title":"J Psychiatry Neurosci JPN"},{"key":"3068_CR22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1614.2003.01279.x","volume":"37","author":"HW Goforth","year":"2003","unstructured":"Goforth HW, Rao MS (2003) Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatr 37:775\u2013776","journal-title":"Aust N Z J Psychiatr"},{"key":"3068_CR23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNF.0b013e31823349ac","volume":"34","author":"P Golubchik","year":"2011","unstructured":"Golubchik P, Sever J, Weizman A (2011) Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 34:216\u2013219","journal-title":"Clin Neuropharmacol"},{"key":"3068_CR24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","volume":"35","author":"AY Hardan","year":"2005","unstructured":"Hardan AY, Jou RJ, Handen BL (2005) Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35:387\u2013391","journal-title":"J Autism Dev Disord"},{"key":"3068_CR25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/cap.2011.0129","volume":"22","author":"JG Ho","year":"2012","unstructured":"Ho JG, Caldwell RL, McDougle CJ, Orsagh-Yentis DK, Erickson CA, Posey DJ, Stigler KA (2012) The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adoles Psychopharmacol 22:277\u2013283","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","volume":"16","author":"E Hollander","year":"2006","unstructured":"Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder. J Child Adoles Psychopharmacol 16:541\u2013548","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","volume":"22","author":"C Kemner","year":"2002","unstructured":"Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455\u2013460","journal-title":"J Clin Psychopharmacol"},{"key":"3068_CR28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2009.0057","volume":"20","author":"S Lambrey","year":"2010","unstructured":"Lambrey S, Falissard B, Martin-Barrero M, Bonnefoy C, Quilici G, Rosier A, Guillin O (2010) Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adoles Psychopharmacol 20:79\u201380","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","volume":"40","author":"RP Malone","year":"2001","unstructured":"Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001) Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40:887\u2013894","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","volume":"41","author":"RP Malone","year":"2002","unstructured":"Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140\u2013147","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR31","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","volume":"17","author":"RP Malone","year":"2007","unstructured":"Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adoles Psychopharmacol 17:779\u2013790","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","volume":"48","author":"RN Marcus","year":"2009","unstructured":"Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110\u20131119","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR33","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.09m05933","volume":"72","author":"RN Marcus","year":"2011","unstructured":"Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL (2011) Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 72:1270\u20131276","journal-title":"J Clin Psychiatry"},{"key":"3068_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","volume":"9","author":"A Martin","year":"1999","unstructured":"Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adoles Psychopharmacol 9:99\u2013107","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","volume":"161","author":"A Martin","year":"2004","unstructured":"Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125\u20131127","journal-title":"Am J Psychiatry"},{"key":"3068_CR36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/00004583-200110000-00015","volume":"40","author":"G Masi","year":"2001","unstructured":"Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206\u20131214","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR37","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314\u2013321","journal-title":"N Engl J Med"},{"key":"3068_CR38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","volume":"41","author":"CJ McDougle","year":"2002","unstructured":"McDougle CJ, Kem DL, Posey DJ (2002) Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41:921\u2013927","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR39","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","volume":"162","author":"CJ McDougle","year":"2005","unstructured":"McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142\u20131148","journal-title":"Am J Psychiatry"},{"issue":"Suppl 4","key":"3068_CR40","first-page":"15","volume":"69","author":"CJ McDougle","year":"2008","unstructured":"McDougle CJ, Stigler KA, Erickson CA, Posey DJ (2008) Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69(Suppl 4):15\u201320","journal-title":"J Clin Psychiatry"},{"key":"3068_CR41","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1542\/peds.2011-0427","volume":"127","author":"ML McPheeters","year":"2011","unstructured":"McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J (2011) A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127:e1312\u2013e1321","journal-title":"Pediatrics"},{"key":"3068_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00787-007-0620-5","volume":"17","author":"S Miral","year":"2008","unstructured":"Miral S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17:1\u20138","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"3068_CR43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","volume":"21","author":"R Nagaraj","year":"2006","unstructured":"Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450\u2013455","journal-title":"J Child Neurol"},{"key":"3068_CR44","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","volume":"124","author":"R Owen","year":"2009","unstructured":"Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533\u20131540","journal-title":"Pediatrics"},{"key":"3068_CR45","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","volume":"37","author":"GJ Pandina","year":"2007","unstructured":"Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F (2007) Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 37:367\u2013373","journal-title":"J Autism Dev Disord"},{"key":"3068_CR46","volume-title":"Clinical manual for the treatment of autism","author":"SK Posey DJ","year":"2007","unstructured":"Posey DJ SK, Erickson CA, McDougle CJ (2007) Treatment of autism with antipsychotics. In: Hollander EAE (ed) Clinical manual for the treatment of autism. American Psychiatric Publishing, Washington"},{"key":"3068_CR47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","volume":"19","author":"MN Potenza","year":"1999","unstructured":"Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37\u201344","journal-title":"J Clin Psychopharmacol"},{"key":"3068_CR48","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network","year":"2005","unstructured":"Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361\u20131369","journal-title":"Am J Psychiatry"},{"key":"3068_CR49","volume-title":"Handbook of psychiatric drug therapy","year":"2005","unstructured":"Rosenbaum JFAG, Hyman SE, Labbate LA, Fava M (eds) (2005) Handbook of psychiatric drug therapy, 5th edn. Lippincott Williams and Wilkins, Philadelphia","edition":"5"},{"key":"3068_CR50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0028-1102913","volume":"42","author":"P Roser","year":"2009","unstructured":"Roser P, Haussleiter IS, Juckel G, Brune M (2009) Paliperidone in an adult patient with Asperger syndrome: case report. Pharmacopsychiatry 42:78\u201379","journal-title":"Pharmacopsychiatry"},{"key":"3068_CR51","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634\u2013e641","journal-title":"Pediatrics"},{"key":"3068_CR52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","volume":"14","author":"KA Stigler","year":"2004","unstructured":"Stigler KA, Posey DJ, McDougle CJ (2004) Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adoles Psychopharmacol 14:455\u2013463","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","volume":"19","author":"KA Stigler","year":"2009","unstructured":"Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ (2009) Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adoles Psychopharmacol 19:265\u2013274","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/cap.2009.0019","volume":"20","author":"KA Stigler","year":"2010","unstructured":"Stigler KA, Erickson CA, Mullett JE, Posey DJ, McDougle CJ (2010) Paliperidone for irritability in autistic disorder. J Child Adoles Psychopharmacol 20:75\u201378","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00213-012-2711-3","volume":"223","author":"KA Stigler","year":"2012","unstructured":"Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ (2012) Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology 223:237\u2013245","journal-title":"Psychopharmacology"},{"key":"3068_CR56","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","volume":"44","author":"PW Troost","year":"2005","unstructured":"Troost PW, Lahuis BE, Steenhuis MP, Ketelaars CE, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137\u20131144","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3068_CR57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/cap.2006.16.549","volume":"16","author":"MR Valicenti-McDermott","year":"2006","unstructured":"Valicenti-McDermott MR, Demb H (2006) Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adoles Psychopharmacol 16:549\u2013560","journal-title":"J Child Adoles Psychopharmacol"},{"key":"3068_CR58","first-page":"738","volume":"153","author":"A Zuddas","year":"1996","unstructured":"Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C (1996) Clinical effects of clozapine on autistic disorder. Am J Psychiatry 153:738","journal-title":"Am J Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3068-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-013-3068-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-013-3068-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:12:47Z","timestamp":1558642367000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-013-3068-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["3068"],"URL":"https:\/\/doi.org\/10.1007\/s00213-013-3068-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}